Published online August 14, 2006
PEDIATRICS Vol. 118 No. 3 September 2006, pp. e635-e640 (doi:10.1542/10.1542/peds.2005-3186)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bierer, R.
Right arrow Articles by Ohls, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bierer, R.
Right arrow Articles by Ohls, R. K.
Related Collections
Right arrow Neurology & Psychiatry
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Erythropoietin Concentrations and Neurodevelopmental Outcome in Preterm Infants

Ryann Bierer, MDa, M. Connie Peceny, BSb, Carol H. Hartenberger, MPHb and Robin K. Ohls, MDb

a Department of Pediatrics, University of Arizona, Tucson, Arizona
b Department of Pediatrics and Pathology, University of New Mexico, Albuquerque, New Mexico

OBJECTIVE. Erythropoietin therapy is effective in decreasing transfusions to varying degrees in preterm infants. Recent animal studies using erythropoietin doses to achieve serum concentrations >1000 mU/mL report neuroprotective effects. We evaluated the relationship between erythropoietin concentrations and neurodevelopmental outcome in extremely low birth weight infants.

METHODS. Preterm infants who weighed ≤1000 g at birth were randomly assigned to erythropoietin (400 U/kg 3 times per week) or placebo/control. Therapy was initiated by 4 days after birth and continued through the 35th postmenstrual week. All infants received supplemental parenteral and enteral iron. Peak serum erythropoietin concentrations were obtained every 2 weeks. Follow-up evaluation included anthropometric measurements, Bayley scales of mental and psychomotor development, neurologic examination, and determination of overall neurodevelopmental impairment. Data were collected at 18 to 22 months' corrected age by certified examiners who were masked to the treatment group. Analyses were performed to identify correlations between erythropoietin concentrations and outcomes.

RESULTS. Sixteen extremely low birth weight infants were enrolled; 1 infant died at 2 weeks (placebo/control), and 15 had erythropoietin concentrations measured (7 erythropoietin, 8 placebo/control). Peak erythropoietin concentrations were significantly different between groups during the study (erythropoietin: 2027 ± 1464 mU/mL; placebo/control: 26 ± 11 mU/mL). Before follow-up, 3 infants died (1 erythropoietin, 2 placebo/control), and 12 were available for follow-up (6 erythropoietin, 6 placebo/control). At 18 to 22 months' follow-up, none of the erythropoietin recipients and 2 of the placebo/control infants had Mental Development Index scores <70. Erythropoietin recipients had Mental Development Index scores of 96 ± 11, and placebo/control infants had Mental Development Index scores of 78 ± 7. Psychomotor Development Index scores were similar between groups (87 ± 13 vs 80 ± 7). There were no differences between groups with respect to anthropometric measurements. Two of 6 infants in the erythropoietin group and 4 of 6 infants in the placebo/control group had some form of neurodevelopmental impairment. Posthoc analysis showed that infants with erythropoietin concentrations ≥500 mU/mL had higher Mental Development Index scores than infants with erythropoietin concentrations <500 mU/mL.

CONCLUSIONS. Erythropoietin concentrations did not correlate with Psychomotor Development Index or overall incidence of neurodevelopmental impairment; however, infants with elevated erythropoietin concentrations had higher Mental Development Index scores than those with lower erythropoietin concentrations. Close follow-up of infants who are enrolled in large, multicenter, high-dose erythropoietin studies is required to determine whether a correlation exists between elevated erythropoietin concentrations and improved neurodevelopmental outcome.

Key Words: erythropoietin • premature infants • neurologic outcome

Abbreviations: NICHD—National Institute of Child Health and Human Development • PMA—postmenstrual age • ELBW—extremely low birth weight • ROP—retinopathy of prematurity • MDI—Mental Development Index • PDI—Psychomotor Development Index • CSF—cerebrospinal fluid

Accepted Mar 8, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
V. Degos, G. Loron, J. Mantz, and P. Gressens
Neuroprotective Strategies for the Neonatal Brain
Anesth. Analg., June 1, 2008; 106(6): 1670 - 1680.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
A. Okumura, H. Kidokoro, T. Kato, T. Kubota, F. Hayakawa, K. Kuno, and K. Watanabe
A Pilot Study on Cord Blood Levels of Erythropoietin and Its Relationship to Periventricular Leukomalacia in Preterm Infants
J Child Neurol, February 1, 2008; 23(2): 231 - 234.
[Abstract] [PDF]